TITLE

Dopamine agonist therapy for hyperprolactinaemia and cardiac valve dysfunction; a lot done but much more to do

AUTHOR(S)
Mark Sherlock
PUB. DATE
April 2009
SOURCE
Heart;Apr2009, Vol. 95 Issue 7, p522
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
36959863

 

Related Articles

  • Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinaemia: a multi-country, nested case-control study. Trifirò G; Mokhles MM; Dieleman JP; van Soest EM; Verhamme K; Mazzaglia G; Herings R; de Luise C; Ross D; Brusselle G; Colao A; Haverkamp W; Schade R; van Camp G; Zanettini R; Sturkenboom MC; Trifirò, Gianluca; Mokhles, M Mostafa; Dieleman, Jeanne P; van Soest, Eva M // Drug Safety;2012, Vol. 35 Issue 2, p159 

    Background: There is growing evidence that ergot dopamine agonists may induce cardiac valve regurgitation (CVR) in persons with Parkinson's disease. It is unclear whether the CVR risk is increased with ergot-dopamine agonist use in persons with hyperprolactinaemia, in whom the dose...

  • Risk of Cardiac Valve Regurgitation with Dopamine Agonist use in Parkinson's Disease and Hyperprolactinaemia: A Multi-Country, Nested Case-Control Study. Trifirô, Gianluca; Mokhles, M. Mostafa; Dieleman, Jeanne P.; van Soest, Eva M.; Verhamme, Katia; Mazzaglia, Giampiero; Herings, Ron; de Luise, Cynthia; Ross, Douglas; Brusselle, Guy; Colao, Annamaria; Haverkamp, Wilhelm; Schade, Rene; van Camp, Guy; Zanettini, Renzo; Sturkenboom, Miriam C. // Drug Safety;2012, Vol. 35 Issue 2, p159 

    Background: There is growing evidence that ergot dopamine agonists may induce cardiac valve regurgitation (CVR) in persons with Parkinson's disease. It is unclear whether the CVR risk is increased with ergot-dopamine agonist use in persons with hyperprolactinaemia, in whom the dose is much...

  • Clinical Clips. Russell, John J. // Patient Care;Mar2007, Vol. 41 Issue 3, p37 

    The article presents abstracts of medical research. They include "Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation," "Familial Premature Coronary Artery Disease Mortality and Obstructive Sleep Apnea," and "Treatment of Vasomotor Symptoms of Menopause With Black Cohosh,...

  • Three cases of macroprolactinaemia. Olukoga, A. O.; Dornan, T. L.; Kane, J. W. // Journal of the Royal Society of Medicine;Jul1999, Vol. 92 Issue 7, p342 

    A woman with hirsutism but otherwise symptom-free was found to have a raised serum prolactin and a pituitary microadenoma. The hyperprolactinaemia persisted despite bromocriptine therapy and subsequent pituitary surgery, which yielded a non-functioning adenoma. After a further 15 years with...

  • Pergolide and cabergoline were associated with increased risk for newly diagnosed cardiac valve regurgitation. Schade, R.; Andersohn, F.; Suissa, S.; Haverkamp, W.; Garbe, E. // ACP Journal Club;May/Jun2007, Vol. 146 Issue 3, p75 

    The article presents a study which examines whether dopamine agonists increase the risk of newly diagnosed cardiac valve regurgitation in patients taking anti-Parkinsonian drugs. Results revealed that the use of pergolide and cabergoline has led to higher risk of newly diagnosed cardiac valve...

  • Parkinson's Drug Raises Risk of Cardiac Valve Regurgitation.  // Neurology Reviews;Apr2007, Vol. 15 Issue 4, p42 

    The article presents a new study conducted by Richard B. Dewey from the University of Texas Southwestern Medical Center in Dallas and colleagues which show that the long-term use of pergolide for Parkinson's disease increases the risk of cardiac valve regurgitation. The occurrence of cardiac...

  • Hyperprolactinaemia in Antipsychotic-Treated Patients: Guidelines for Avoidance and Management. Hamner, M.B.; Arana, G.W. // CNS Drugs;1998, Vol. 10 Issue 3, p209 

    Elevated prolactin (PRL) levels have been considered virtually unavoidable in most patients treated with therapeutic doses of traditional antipsychotics. Clinical effects of such hyperprolactinaemia may include amenorrhoea, galactorrhoea and sexual dysfunction. For clinical symptoms, the...

  • Testosterone replacement-induced hyperprolactinaemia: case report and review of the literature. Sodi, R; Fikri, R; Diver, M; Ranganath, L; Vora, J // Annals of Clinical Biochemistry;Feb2005, Vol. 42 Issue 2, p153 

    Half of all men with prolactin (PRL)-producing macroadenomas present with hypogonadism, decreased libido and impotence, and therefore require testosterone replacement. However, very little is known about the effect of testosterone on prolactinomas. We report a case of an 18-year-old obese man...

  • Parkinson's treatment may increase risk of heart disorder.  // Geriatrics;Mar2007, Vol. 62 Issue 3, p15 

    The article provides information on the results of two studies on the risk of having heart valve regurgitation in using dopamine agonists pergolide and cabergoline to treat Parkinson's disease. The "Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation," conducted by physician Rene...

  • Die Therapie der Parkinsonerkrankung mit Dopaminagonisten. Konta, Brigitte; Frank, Wilhelm // GMS Health Technology Assessment;2009, Vol. 5, p1 

    Parkinson's disease is a chronic degenerative organic disease with unknown causes. A disappearance of cells with melanin in the substantia nigra is considered as biological artefact of the disease, which causes a degenerative loss of neurons in the corpus striatum of mesencephalon. This...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics